Alucent Biomedical Announces Formation of Scientific Advisory Board

, a privately held biotechnology company founded to
transform the way vascular disease is treated, today announced the
formation of its scientific
advisory board
with seven key appointments: Gary Ansel, M.D.; Elazar
Edelman, M.D., Ph.D.; William Gray, M.D.; Larry Kraiss, M.D.; Krishna
Rocha-Singh, M.D.; William Sessa, Ph.D. and Craig Walker, M.D.

The board will work closely with the Alucent management team as it
continues to advance Natural
Vascular Scaffolding™
(NVS), its breakthrough combination
drug-device therapy designed to naturally open narrowed or blocked
arteries, possibly replacing the need for a stent.

“Alucent is honored to have attracted to its scientific advisory board a
team of leading experts in peripheral and cardiovascular disease who see
great potential in our novel drug-device therapy,” said Myles Greenberg,
M.D., president and chief executive officer of Alucent Biomedical. “The
board’s combined expertise will be invaluable as we continue to
investigate NVS, a treatment option developed to address the unmet need
of patients with difficult-to-treat peripheral artery disease.”

About the Alucent Biomedical Scientific
Advisory Board

Dr. Gary Ansel is an internationally renowned interventional expert,
both in peripheral vascular and cardiovascular procedures. He has been
appointed associate medical director of the OhioHealth Research and
Innovation Institute in Columbus, Ohio and is a member of the OhioHealth
Research Industry Council. He serves as a primary investigator for
numerous national and international research trials, helping to improve
care for patients suffering with peripheral and cardiovascular disease.
Currently, he is system medical chief, Vascular Program – OhioHealth,
and assistant clinical professor of medicine in the Department of
Internal Medicine at the University of Toledo Medical Center, Toledo,
Ohio. Dr. Ansel is a founding board member of the Vascular
InterVentional Advances Conference (VIVA), a non-profit organization
dedicated to education and research of vascular disease. He received his
Doctor of Medicine degree from Ohio State University College of
Medicine, where he also completed a postgraduate research fellowship in
cardiology. He completed his residency and internship at the Medical
University of Ohio in Toledo and received his post-fellowship training
in peripheral vascular intervention at the Ochsner Clinic in New Orleans.

Dr. Elazer R. Edelman is the Thomas D. and Virginia W. Cabot Professor
of Health Sciences and Technology at MIT, professor of medicine at
Harvard Medical School, and senior attending physician in the coronary
care unit at the Brigham and Women’s Hospital (BWH) in Boston. He and
his laboratory have pioneered basic findings in vascular biology and the
development and assessment of biotechnology. Dr. Edelman directs the
Harvard-MIT Biomedical Engineering Center (BMEC), dedicated to applying
the rigors of the physical sciences to elucidate fundamental biologic
processes and mechanisms of disease. He received Bachelor of Science
degrees in bioelectrical engineering and applied biology from the
Massachusetts Institute of Technology (MIT), a Master of Science degree
in electrical engineering and computer sciences from MIT, a Ph.D. in
Medical Engineering and Medical Physics from MIT, and a medical degree
from Harvard Medical School. After internal medicine training and
clinical fellowship in cardiovascular medicine at the BWH, he spent six
years as a research fellow in the Department of Pathology at Harvard
Medical School working on the biology of vascular repair. His research
interests meld his medical and scientific training to better understand
underlying biology for application towards improved clinical
decision-making and device design.

Dr. William Gray is system chief of the Division of Cardiovascular
Disease at Main Line Health in Philadelphia. He is also the first
president of Main Line Health’s Lankenau Heart Institute, the system’s
comprehensive cardiovascular medicine and surgery program. Dr. Gray has
served in cardiovascular leadership roles for nearly 20 years, most
recently as director of endovascular services at New
York-Presbyterian/Columbia University Medical Center, and from 1999 to
2005 as director of endovascular services at Swedish Medical Center in
Seattle. In addition to his leadership positions, Dr. Gray has been
instrumental in growing the field of endovascular medicine through
clinical training program development and oversight. He started the
endovascular fellowship program at Swedish Medical Center in 2002 and
served as its director for three years. He then launched and directed
the endovascular fellowship program in the Cardiology Division of
Columbia University College of Physicians and Surgeons. Dr. Gray is
board-certified in internal medicine, general cardiology and
interventional cardiology, as well as in endovascular and vascular
medicine. He earned his medical degree from Temple University School of
Medicine. He completed an internal medicine residency and year as chief
resident at Brown University/Rhode Island Hospital, where he also
completed cardiology and interventional cardiology fellowships. Dr. Gray
is a fellow of the American College of Cardiology and the Society for
Cardiac Angiography and Intervention. He serves on the editorial board
of JACC Cardiac Interventions and is a reviewer for several other
peer-reviewed cardiovascular publications.

Dr. Larry W. Kraiss is Professor of Surgery in the Division of Vascular
Surgery at the University of Utah. He is a graduate of Vanguard
University of Southern California and Baylor College of Medicine (MD).
He took his general and vascular surgical training at the University of
Washington in Seattle, where he also spent three years in the vascular
biology research laboratory of Dr. Alexander Clowes. He joined the
faculty at the University of Utah in 1995, where he established an
NIH-funded research laboratory studying translational control in
endothelial cells and was named vascular surgery division chief in 2003.
He was director of the vascular surgery fellowship program at the
University of Utah from 2003 to 2012 and chief of vascular surgery from
2003 to 2018. He maintains a broad-based vascular surgery practice at
the University of Utah. More recently, he has developed an academic
interest in frailty and its role in pre-operative decision-making in
vascular surgery. He is a regular reviewer for research proposals
submitted to the NIH, NASA, and the Society for Vascular Surgery (SVS).
He has served as Chair of the SVS Research Council and Chair of the
Arterial Quality Committee of the SVS Patient Safety Organization. He is
a past president of the Western Vascular Society. He currently serves as
Chair of the Governing Council of the SVS Patient Safety Organization.

Dr. Krishna Rocha-Singh is chief scientific officer for Prairie Heart
Institute at St. John’s Hospital in Springfield, Ill. In addition, he is
a current co-founding board member of Vascular InterVentional Advances
(VIVA), a not-for-profit organization dedicated to advancing the field
of vascular medicine and intervention through education and research. In
his role as VIVA’s research director, he has collaborated with the Food
and Drug Administration (FDA) in developing several objective
performance criteria, which are currently being used by the industry for
clinical trials of nitinol stents in symptomatic peripheral arterial
disease and resistant hypertension secondary to atherosclerotic
renovascular disease. Dr. Rocha-Singh has served as a board or committee
member on numerous medical societies including the American College of
Cardiology, American Board of Vascular Medicine and Society of
Cardiovascular Angiography and Intervention, and is presently on several
academic journal editorial boards. Dr. Rocha-Singh has authored over 100
books, book chapters and peer-reviewed manuscripts on coronary and
peripheral endovascular interventional subjects. A board-certified
cardiologist, he holds a medical degree from the University of
California, Los Angeles; completed residency at University of Colorado,
Denver; and a Cardiology Fellowship at the University of California, San
Francisco, California & Scripps Clinic & Research Foundation, La Jolla.

Dr. William Sessa is the Alfred Gilman Professor of Pharmacology and
Professor of Medicine (Cardiology); the vice chairman, pharmacology; and
the director, Vascular Biology & Therapeutics Program at Yale
University. Dr. Sessa’s numerous honors include the American Heart
Association’s Established Investigator Award; the Young Alumnus Award;
the Experimental Therapeutics’ John J. Abel Award in Pharmacology, a
MERIT Award; and The Robert Berne Award from the American Physiological
Society. He is also a recipient of the William Harvey Medal. He has
served on numerous editorial and scientific advisory boards, and has
been an invited lecturer at universities and research institutes
throughout the United States, in Latin America and in Europe. He has
authored or co-authored more than 200 research articles and papers. Dr.
Sessa joined the Yale faculty in 1993 as an assistant professor of
pharmacology after post-doctoral work at the University of Virginia
Health Sciences Center, School of Medicine. He earned his Ph.D. at New
York Medical College and was a postdoctoral fellow and senior scientist
at the William Harvey Research Institute at St. Bartholomew’s Hospital
Medical College in London.

Dr. Craig Walker is the founder and president of the Cardiovascular
Institute of the South. Board certified in internal medicine,
cardiovascular disease and interventional cardiology, he is a fellow of
the American College of Cardiology, the American College of Physicians,
the American Society of Cardiovascular Interventionists, the
International College of Angiology, the Society for Cardiac Angiography
and Interventions, the American College of Chest Physicians, and the
Council on Clinical Cardiology. Dr. Walker founded and is the chairman
of one of the largest cardiovascular conferences in the nation, New
Cardiovascular Horizons, which educates and trains medical professionals
on the latest techniques to treat coronary and peripheral vascular
disease. He has also been the primary investigator for several
cardiovascular and peripheral devices. Dr. Walker serves as a clinical
editor of Vascular Disease Management (VDM) and editor for Global
Vascular Digest, and he is on the editorial boards for Endovascular
Today and the Journal of Endovascular Therapy. He earned his medical
degree from the Louisiana State University (LSU) School of Medicine in
New Orleans. He began his postgraduate training with an internship and
residency at Lafayette Charity Hospital in Lafayette, Louisiana. He
continued his training with a cardiology fellowship at Ochsner
Foundation Hospital in New Orleans and a research fellowship at Harvard
Medical School in Boston.

About Natural Vascular Scaffolding (NVS)

NVS is performed in concert with standard balloon angioplasty
technique. Standard angioplasty stretches the vessel wall and causes
breakage of the natural links between the native collagen that provides
structural stability to the artery. During the interventional procedure,
a light-activated, novel small molecule medicine is delivered to the
wall of the diseased artery, where it diffuses into the tissue. A NVS
light fiber is illuminated, activating the drug. The drug then flexibly
re-links the native collagen, a major structural component of the vessel
wall, leaving it closer to its natural state. This linking restores the
structure and function of the collagen, creating a natural scaffold, or
stent, that holds open the vessel. NVS has the potential to improve
long-term clinical outcomes in the treatment of PAD. NVS may reduce or
eliminate the need for metallic stents in patients with PAD. The therapy
also has the potential to reduce treatment complications as well as
unnecessary costs to the healthcare system. Its potential durability may
also reduce the complications and costs associated with re-interventions.

About Alucent Biomedical

Alucent Biomedical, Inc. is a privately held biotechnology company
headquartered in Salt Lake City, Utah and is the first company to bring
a novel, locally delivered biotechnology treatment to a market
traditionally dominated by medical device solutions. Alucent was founded
by Avera
to develop and market Natural Vascular Scaffolding (NVS). NVS
is a first-of-a-kind combination drug-device therapy designed to assist
the body in naturally opening and maintaining arterial patency.


Alucent Biomedical, Inc.
Diana Soltesz, 818-618-5634

Sky Optics Media drone video